NCT00104052View on ClinicalTrials.gov

Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)

PHASE3CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Hepatitis C, Chronic
Interventions
BIOLOGICAL

peginterferon alfa-2b (PEG2b) (SCH 54031)

PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.

DRUG

ribavirin (SCH 18908)

15 mg/kg/day for up to 48 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00104052 - Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1) | Biotech Hunter | Biotech Hunter